Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IRADIMED CORPIRMD · Entity 4896 | Director · CEO, President, Chairman · 10% owner | June 01, 2026 | June 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IRADIMED CORP
Report date June 01, 2026 · Filed June 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Phillip Susi 2008 Dynasty Trust | 2,164,600 |
Reported balance
After 2026-06-01 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-06-01 · Sale · Disposed 400 · Balance 2,164,600 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025. F2: This transaction was executed in multiple trades at prices ranging from $88.10 to $88.87. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Common StockSEC Table I · non-derivative | IndirectBy Phillip Susi 2008 Dynasty Trust | 2,163,825 |
Reported balance
After 2026-06-01 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-06-01 · Sale · Disposed 775 · Balance 2,163,825 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025. F3: This transaction was executed in multiple trades at prices ranging from $89.29 to $90.15. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Common StockSEC Table I · non-derivative | IndirectBy Phillip Susi 2008 Dynasty Trust | 2,163,424 |
Reported balance
After 2026-06-01 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-06-01 · Sale · Disposed 401 · Balance 2,163,424 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025. F4: This transaction was executed in multiple trades at prices ranging from $90.69 to $91.58. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Common StockSEC Table I · non-derivative | IndirectBy Phillip Susi 2008 Dynasty Trust | 2,162,500 |
Reported balance
After 2026-06-01 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2026-06-01 · Sale · Disposed 924 · Balance 2,162,500 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025. F5: This transaction was executed in multiple trades at prices ranging from $91.75 to $92.08. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Common StockSEC Table I · non-derivative | IndirectBy Roger E. Susi Revocable Trust | 162,950 |
Reported balance
Holding disclosure · report date 2026-06-01 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 162,950 |
| Common StockSEC Table I · non-derivative | IndirectBy Matthew Susi 2008 Dynasty Trust | 2,062,500 |
Reported balance
Holding disclosure · report date 2026-06-01 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 2,062,500 F6: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025.
F2: This transaction was executed in multiple trades at prices ranging from $88.10 to $88.87. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: This transaction was executed in multiple trades at prices ranging from $89.29 to $90.15. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4: This transaction was executed in multiple trades at prices ranging from $90.69 to $91.58. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5: This transaction was executed in multiple trades at prices ranging from $91.75 to $92.08. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 05, 2023 Filed Sep 6, 2023 20:10 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 10,000 | $47.59 | $475,939.00 |
DisclosureSEC source: 0001415889-23-012975 · form4-09062023_040901.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 322,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $47.31 to $48.01. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 29, 2023 Filed Aug 30, 2023 20:15 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 3,008 | $48.05 | $144,530.79 |
DisclosureSEC source: 0001415889-23-012802 · form4-08302023_040804.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 332,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $46.55 to $48.75. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 28, 2023 Filed Aug 30, 2023 20:15 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 6,992 | $47.00 | $328,656.86 |
DisclosureSEC source: 0001415889-23-012802 · form4-08302023_040804.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 335,958 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $46.19 to $48.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 22, 2023 Filed Aug 23, 2023 20:10 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 10,000 | $47.40 | $473,981.00 |
DisclosureSEC source: 0001415889-23-012553 · form4-08232023_040801.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 342,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $46.88 to $48.14. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 14, 2023 Filed Aug 15, 2023 20:15 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 10,000 | $48.55 | $485,495.00 |
DisclosureSEC source: 0001415889-23-012260 · form4-08152023_040803.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 352,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $47.93 to $48.82. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 07, 2023 Filed Aug 8, 2023 20:15 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 10,000 | $49.60 | $496,034.00 |
DisclosureSEC source: 0001415889-23-011927 · form4-08082023_040806.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 362,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $48.49 to $50.61. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 02, 2023 Filed Aug 3, 2023 20:05 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $44.02 | $220,079.50 |
DisclosureSEC source: 0001415889-23-011804 · form4-08032023_040802.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 372,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $43.29 to $45.04. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 20:05 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $44.59 | $222,950.00 |
DisclosureSEC source: 0001415889-23-011804 · form4-08032023_040802.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 377,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $43.56 to $45.61. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 26, 2023 Filed Jul 27, 2023 00:05 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 3,276 | $45.90 | $150,377.57 |
DisclosureSEC source: 0001415889-23-011518 · form4-07262023_080701.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 382,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $44.19 to $46.25. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · price: This transaction was executed in multiple trades at prices ranging from $45.04 to $46.45. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 24, 2023 Filed Jul 27, 2023 00:05 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 6,724 | $45.02 | $302,696.33 |
DisclosureSEC source: 0001415889-23-011518 · form4-07262023_080701.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 386,226 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $44.19 to $46.25. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 17, 2023 Filed Jul 18, 2023 20:15 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 10,000 | $45.70 | $456,983.00 |
DisclosureSEC source: 0001415889-23-011229 · form4-07182023_040702.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 392,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $44.83 to $46.35 . The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 12, 2023 Filed Jul 13, 2023 20:15 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 3,496 | $46.27 | $161,763.07 |
DisclosureSEC source: 0001415889-23-011075 · form4-07132023_040702.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 402,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $45.68 to $46.62. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 20:15 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 6,504 | $46.39 | $301,717.31 |
DisclosureSEC source: 0001415889-23-011075 · form4-07132023_040702.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 406,446 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $46.01 to $47.44. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 06, 2023 Filed Jul 7, 2023 20:15 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 8,556 | $45.67 | $390,738.83 |
DisclosureSEC source: 0001415889-23-010943 · form4-07072023_040702.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 412,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $45.10 to $46.06. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 05, 2023 Filed Jul 7, 2023 20:15 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 1,444 | $47.00 | $67,874.06 |
DisclosureSEC source: 0001415889-23-010943 · form4-07072023_040702.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 421,506 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $47.00 to $47.11. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 28, 2023 Filed Jun 28, 2023 21:05 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 6,916 | $47.32 | $327,280.34 |
DisclosureSEC source: 0001415889-23-010416 · form4-06282023_050602.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 422,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $47.10 to $48.57. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 27, 2023 Filed Jun 28, 2023 21:05 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 3,084 | $49.09 | $151,378.45 |
DisclosureSEC source: 0001415889-23-010416 · form4-06282023_050602.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 429,866 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $48.50 to $49.34. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 21, 2023 Filed Jun 21, 2023 20:30 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 2,117 | $47.40 | $100,348.55 |
DisclosureSEC source: 0001415889-23-010097 · form4-06212023_040604.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 432,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $47.06 to $47.47. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 20, 2023 Filed Jun 21, 2023 20:30 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 7,883 | $48.67 | $383,685.32 |
DisclosureSEC source: 0001415889-23-010097 · form4-06212023_040604.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · CEO, PRESIDENT, CHAIRMAN · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 435,067 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $48.00 to $50.40. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 12, 2023 Filed Jun 12, 2023 21:48 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 10,000 | $47.36 | $473,552.00 |
DisclosureSEC source: 0000898432-23-000367 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 442,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $46.46 to $47.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 13:15 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 10,000 | $46.78 | $467,756.00 |
DisclosureSEC source: 0000898432-23-000365 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 452,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $46.46 to $47.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 31, 2023 Filed Jun 1, 2023 15:02 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 4,175 | $46.31 | $193,354.69 |
DisclosureSEC source: 0000898432-23-000350 · form4.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 462,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $46.01 to $46.56. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 30, 2023 Filed Jun 1, 2023 15:02 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,825 | $46.27 | $269,550.71 |
DisclosureSEC source: 0000898432-23-000350 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 467,125 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $45.27 to $47.37. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 22, 2023 Filed May 23, 2023 15:56 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 10,000 | $45.95 | $459,507.00 |
DisclosureSEC source: 0000898432-23-000328 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 472,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $45.22 to $46.58. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 16, 2023 Filed May 16, 2023 20:04 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 3,258 | $45.32 | $147,659.73 |
DisclosureSEC source: 0000898432-23-000310 · form4.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 482,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $45.00 to $45.53. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 15, 2023 Filed May 16, 2023 20:04 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 6,742 | $46.27 | $311,942.90 |
DisclosureSEC source: 0000898432-23-000310 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 486,208 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $46.00 to $47.11. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 10, 2023 Filed May 11, 2023 15:49 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 7,521 | $46.50 | $349,712.21 |
DisclosureSEC source: 0000898432-23-000287 · form4.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 492,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $46.00 to $47.90. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 09, 2023 Filed May 11, 2023 15:49 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 2,479 | $48.04 | $119,081.74 |
DisclosureSEC source: 0000898432-23-000287 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 500,471 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $47.50 to $48.62. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 05, 2023 Filed May 8, 2023 22:40 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 10,000 | $46.20 | $461,976.00 |
DisclosureSEC source: 0000898432-23-000272 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 502,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $46.00 to $46.48. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 24, 2023 Filed Apr 24, 2023 23:27 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 10,000 | $41.23 | $412,324.00 |
DisclosureSEC source: 0000898432-23-000213 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 512,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $40.96 to $41.89. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 17, 2023 Filed Apr 17, 2023 20:56 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 10,000 | $39.69 | $396,925.00 |
DisclosureSEC source: 0000898432-23-000202 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 522,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $39.32 to $40.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 10, 2023 Filed Apr 11, 2023 16:09 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 10,000 | $40.26 | $402,577.00 |
DisclosureSEC source: 0000898432-23-000199 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 532,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $39.70 to $41.16. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 03, 2023 Filed Apr 3, 2023 21:52 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 10,000 | $38.71 | $387,066.00 |
DisclosureSEC source: 0000898432-23-000198 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 542,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $38.37 to $39.48. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 16:41 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 10,000 | $38.11 | $381,082.00 |
DisclosureSEC source: 0000898432-23-000177 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 552,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $37.30 to $38.69. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 20, 2023 Filed Mar 21, 2023 22:21 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 10,000 | $37.45 | $374,530.00 |
DisclosureSEC source: 0000898432-23-000165 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 562,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $37.00 to $38.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 13, 2023 Filed Mar 15, 2023 14:35 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 10,000 | $37.81 | $378,117.00 |
DisclosureSEC source: 0000898432-23-000162 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 572,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $37.33 to $38.53. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 07, 2023 Filed Mar 7, 2023 22:53 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 4,516 | $38.88 | $175,582.08 |
DisclosureSEC source: 0000898432-23-000151 · form4.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 582,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $38.52 to $39.24. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 06, 2023 Filed Mar 7, 2023 22:53 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,484 | $38.52 | $211,243.68 |
DisclosureSEC source: 0000898432-23-000151 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 587,466 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $38.50 to $38.59. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 28, 2023 Filed Feb 28, 2023 18:40 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 237 | $37.50 | $8,887.50 |
DisclosureSEC source: 0000898432-23-000127 · form4.xml · nonDerivative · entry 2 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 592,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $37.50 to $37.51. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 27, 2023 Filed Feb 28, 2023 18:40 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 9,763 | $37.79 | $368,943.77 |
DisclosureSEC source: 0000898432-23-000127 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 593,187 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $37.27 to $38.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 23:26 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 10,000 | $36.75 | $367,500.00 |
DisclosureSEC source: 0000898432-23-000119 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 602,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $36.37 to $37.09. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 21:04 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 10,000 | $35.50 | $355,000.00 |
DisclosureSEC source: 0000898432-23-000095 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 612,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $34.98 to $36.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 17:05 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 10,000 | $35.50 | $355,000.00 |
DisclosureSEC source: 0000898432-23-000092 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 612,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $34.98 to $36.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 03, 2022 Filed May 4, 2022 23:10 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 10,000 | $33.53 | $335,298.00 |
DisclosureSEC source: 0000898432-22-000322 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 622,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $33.14 to $34.11. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 27, 2022 Filed Apr 28, 2022 21:32 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 10,000 | $40.50 | $404,996.00 |
DisclosureSEC source: 0000898432-22-000316 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 632,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $39.52 to $41.53. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 19, 2022 Filed Apr 21, 2022 11:43 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 10,000 | $43.90 | $439,023.00 |
DisclosureSEC source: 0000898432-22-000288 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 642,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $42.44 to $43.52. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 12, 2022 Filed Apr 13, 2022 21:46 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 10,000 | $42.90 | $429,012.00 |
DisclosureSEC source: 0000898432-22-000273 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 652,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $42.44 to $43.52. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 07, 2022 Filed Apr 8, 2022 20:08 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 10,000 | $45.35 | $453,530.00 |
DisclosureSEC source: 0000898432-22-000265 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 662,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $44.50 to $45.75. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 28, 2022 Filed Mar 30, 2022 11:38 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 10,000 | $52.95 | $529,546.00 |
DisclosureSEC source: 0000898432-22-000229 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 672,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $52.10 to $54.23. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 21, 2022 Filed Mar 22, 2022 20:09 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 10,000 | $50.08 | $500,802.00 |
DisclosureSEC source: 0000898432-22-000223 · form4.xml · nonDerivative · entry 1 Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Roger E. Susi Revocable Trust Disclosed balance after: 682,950 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $49.70 to $50.93. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.